Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of favipiravir丨cas 259793-96-9 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
|
Property |
Specification |
|
Appearance |
Off-white to light yellow powder |
|
Assay (anhydrous substance) |
98.0% ~ 102.0% |
|
Solubility |
Sparingly soluble in methanol, sparingly soluble in acetonitrile, and slightly soluble in water and anhydrous ethanol |
|
Melting point |
187 ~ 193°C |
|
Heavy metals |
20 ppm max |
|
Chlorides |
0.06% max |
|
Water |
1.0% max |
|
Particle size distribution (D90) |
20 μm max |
|
Individual impurity |
0.05% max |
|
Total impurities |
0.5% max |
|
Residual Solvent |
Ethanol: 5000 ppm max |
|
Residue on ignition |
0.1% max |
Transport Information of Favipiravir丨CAS 259793-96-9
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2933990099306 |
|
Stability & Reactivity |
Stable |
|
Storage |
-20℃ |
|
Condition to Avoid |
Keep away from moisture. Strong heating. |
|
Package |
Introduction of Favipiravir丨CAS 259793-96-9
Favipiravir丨CAS 259793-96-9 is an antiviral medication primarily used to treat certain viral infections. It is known for its broad-spectrum activity against various RNA viruses. Here are its applications and benefits:
Applications of Favipiravir丨CAS 259793-96-9
1. Treatment of Influenza:
- Influenza Virus: Favipiravir丨CAS 259793-96-9 is used to treat influenza, particularly in cases where conventional antiviral drugs (like oseltamivir) are not effective. It can be used in both seasonal influenza and pandemic strains.
2. Treatment of COVID-19:
- COVID-19: Favipiravir has been used as a treatment option for COVID-19, especially in the early stages of infection. It is included in some COVID-19 treatment protocols, though its efficacy varies, and it is often used in combination with other antiviral or supportive therapies.
3. Treatment of Other Viral Infections:
- Ebola Virus: Favipiravir has been investigated for its potential use against Ebola virus disease, although its primary use in this regard is limited.
- Other RNA Viruses: Research is ongoing into Favipiravir's effectiveness against other RNA viruses, such as the Lassa fever virus and certain emerging viruses.
4. Experimental Uses:
- Clinical Trials: Favipiravir is being studied in clinical trials for its potential use against other viral infections, including some that are not yet well-established or are in outbreak situations.
Benefits of Favipiravir丨CAS 259793-96-9
1. Broad-Spectrum Antiviral Activity:
- Wide Range of Viruses: Favipiravir丨CAS 259793-96-9 exhibits activity against a broad range of RNA viruses, making it a versatile antiviral agent. This broad-spectrum activity can be beneficial in treating various viral infections.
2. Effective in Early Stages of Infection:
- Early Intervention: Favipiravir is most effective when administered early in the course of infection. It helps reduce viral replication and can shorten the duration of illness when used promptly.
3. Oral Administration:
- Convenient Formulation: Favipiravir is available in an oral formulation, which makes it easier to administer compared to some other antiviral treatments that require intravenous administration.
4. Potential for Use in Outbreaks:
- Emergency Response: Its broad-spectrum activity and oral administration make Favipiravir a valuable tool in managing viral outbreaks, providing a treatment option for emerging or re-emerging viral diseases.
5. Potential for Combination Therapy:
- Synergistic Effects: Favipiravir can be used in combination with other antiviral medications or supportive treatments, which can enhance overall therapeutic efficacy and potentially improve outcomes.
6. Research and Development:
- Ongoing Studies: The continued research into Favipiravir's effectiveness against various viruses contributes to the development of new treatment options and enhances our understanding of its therapeutic potential.
7. Reduced Drug Resistance:
- Lower Resistance Rate: Compared to some other antiviral drugs, Favipiravir may have a lower rate of inducing drug resistance, although this is still under investigation.
Conclusion:
Favipiravir丨CAS 259793-96-9 is a broad-spectrum antiviral medication with applications in treating influenza, COVID-19, and potentially other viral infections. Its benefits include effective antiviral activity, convenient oral administration, and potential utility in outbreak situations. Ongoing research continues to explore its effectiveness against various RNA viruses and its role in combination therapy. While Favipiravir has shown promise, its use should be guided by clinical evidence and public health recommendations.
